Inovio Pharmaceuticals (INO) Net Income (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Net Income of -$23.6 million for Q1 2026, down 38.85% sequentially from -$17.0 million in Q4 2025, and up 37.64% YoY from -$17.2 million in Q1 2025.
Inovio Pharmaceuticals (INO) Net Income (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Net Income for 17 years, with the latest figure at -$23.6 million in Q1 2026.
- Quarterly Net Income rose 37.64% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.4 million (up 27.78% YoY) and the FY2025 annual result came in at -$462.9 million, down 1.32% from the prior year.
- Net Income eased to -$23.6 million in Q1 2026 per INO's latest filing, from -$17.0 million in the prior quarter.
- Over five years, Net Income peaked at -$17.0 million in Q4 2025 and troughed at -$108.5 million in Q2 2022.
- A 5-year average of -$38.0 million and a median of -$33.2 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income plunged 42.51% in 2022, then surged 67.25% in 2023.
- Over 5 years, Net Income stood at -$54.5 million in 2022, then jumped by 54.09% to -$25.0 million in 2023, then grew by 21.94% to -$19.5 million in 2024, then increased by 12.76% to -$17.0 million in 2025, then slumped by 38.85% to -$23.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$23.6 million, -$17.0 million, and -$20.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | -18.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.51 Mn |
| Mar 31, 2026 | -23.64 Mn |
| Dec 31, 2025 | -17.03 Mn |
| Sep 30, 2025 | -20.66 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -37.91 Mn |
| Dec 31, 2024 | -19.52 Mn |
| Sep 30, 2024 | -26.24 Mn |
| Jun 30, 2024 | -33.21 Mn |
| Mar 31, 2024 | -32.06 Mn |
| Dec 31, 2023 | -25.00 Mn |
| Sep 30, 2023 | -33.93 Mn |
| Jun 30, 2023 | -35.53 Mn |
| Mar 31, 2023 | -40.65 Mn |
| Dec 31, 2022 | -54.46 Mn |
| Sep 30, 2022 | -37.78 Mn |
| Jun 30, 2022 | -108.50 Mn |
| Mar 31, 2022 | -76.91 Mn |
| Dec 31, 2021 | -106.95 Mn |
| Sep 30, 2021 | -60.17 Mn |